BioWorld

April 28, 2003

View Archived Issues

Stock Winners and Losers For The Week

Biotechnology Company Deals With Other Biotechnology Companies: Collaborations, Agreements, Equity Participation, Feb. 20 - April 23, 2003

Biotechnology Company Deals With Miscellaneous Companies: Collaborations, Agreements, Equity Participation, Feb. 20 - April 23, 2003

Manufacturing, Marketing And Distribution Agreements Between Biotech Companies: Feb. 20 - April 23, 2003

Biotech - Biotech Collaborations: Modified And Terminated Agreements, Feb. 20 - April 23, 2003

BioWorld Stock Report For Public Biotechnology Companies

Psoriasis Survey Finds Market Robust, Room For Many Winners

Familiarity may breed contempt in some settings, but in the prescription world it often means a leg up on competing drugs. Such appears to be the case with Enbrel (etanercept), Amgen Inc.'s rheumatoid arthritis treatment approved in 1998. Read More

Money Raised Year To Date

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...